BMS in China: 36 years devoted to both innovation and health

The continuous improvement of China's economy and policies over the past 40 years has brought unprecedented opportunities for foreign enterprises, indispensable participants in the all-round development of the country.

Responding to the reform and opening-up wave, global biopharma leader Bristol-Myers Squibb entered China has been striving to accelerate its innovations in this era of transformation for China's modern pharmaceutical industry.

"Through unceasingly addressing China's medical needs, BMS has handed over a satisfactory answer to the Chinese people with medical research breakthroughs and therapies," said Shirley Zhao, general manager and president of Bristol-Myers Squibb Chinese Mainland and Hong Kong.